Achilles Therapeutics plc
- Jurisdiction
United Kingdom - LEI
984500FDESEB1BE52A76 - ISIN
US00449L1026 (ACHL )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€60.81M - EBIT margin
0.0% - Net income
-€55.02M - Net margin
0.0%
Statement period: - (published )
Dividends
No dividend payouts